Linagliptin plasma concentration and DPP-4 inhibition measurements from a placebo-controlled , parallel group multiple ( 28 days ) dose trial that included 36 T2DM patients ( 18 patients each in 2.5 mg and 10 mg dose group ) were used for analysis .